Compare · ABBV vs MURF
ABBV vs MURF
Side-by-side comparison of AbbVie Inc. (ABBV) and Murphy Canyon Acquisition Corp. (MURF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and MURF operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV carries a market cap of $434.78B.
- ABBV has hit the wire 16 times in the past 4 weeks while MURF has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 0 for MURF).
- Company
- AbbVie Inc.
- Murphy Canyon Acquisition Corp.
- Price
- $245.96+0.87%
- $17.48-1.52%
- Market cap
- $434.78B
- -
- 1M return
- -1.54%
- -
- 1Y return
- +24.21%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2022
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Murphy Canyon Acquisition Corp.
Murphy Canyon Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on identifying businesses in the real estate industry, including construction, homebuilding, real estate owners and operators, arrangers of financing, insurance, and other services for real estate, and adjacent businesses and technologies targeting the real estate space. The company was incorporated in 2021 and is based in San Diego, California.
Latest ABBV
- SEC Form 424B5 filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- AbbVie upgraded by Erste Group
- SEC Form FWP filed by AbbVie Inc.
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- SEC Form 424B5 filed by AbbVie Inc.
- Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
- UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment
- SEC Form 10-Q filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest MURF
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form S-8 filed by Murphy Canyon Acquisition Corp.
- SEC Form 424B3 filed by Murphy Canyon Acquisition Corp.
- SEC Form EFFECT filed by Murphy Canyon Acquisition Corp.
- SEC Form 4 filed by Lewis-Hall Freda C
- SEC Form 4 filed by Mcnealey Jennifer Isacoff
- SEC Form 4 filed by Bligh James
- SEC Form 4 filed by Farley Chele Chiavacci